Latest Insider Transactions at Cyclo Therapeutics, Inc. (CYTH)
This section provides a real-time view of insider transactions for Cyclo Therapeutics, Inc. (CYTH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cyclo Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cyclo Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 20
2023
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
59,881
+27.1%
|
$0
$0.71 P/Share
|
|
Apr 20
2023
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
299,402
+40.25%
|
$0
$0.71 P/Share
|
|
Nov 08
2022
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,097
+8.25%
|
-
|
|
Nov 08
2022
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,496
+8.58%
|
-
|
|
Nov 08
2022
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,803
+6.77%
|
-
|
|
Sep 21
2022
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+3.21%
|
$5,000
$1.76 P/Share
|
|
Aug 02
2022
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,093
+5.65%
|
-
|
|
Aug 02
2022
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,762
+5.91%
|
-
|
|
Aug 02
2022
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,162
+4.69%
|
-
|
|
May 20
2022
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+1.74%
|
$10,000
$2.02 P/Share
|
|
May 16
2022
|
Jeffrey Tate Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+8.53%
|
$6,000
$2.12 P/Share
|
|
May 03
2022
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,267
+4.46%
|
-
|
|
May 03
2022
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,223
+4.69%
|
-
|
|
May 03
2022
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,249
+3.78%
|
-
|
|
Apr 29
2022
|
Jeffrey Tate Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
1,365
+2.29%
|
$2,730
$2.71 P/Share
|
|
Apr 28
2022
|
Jeffrey Tate Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
635
+2.23%
|
$1,270
$2.5 P/Share
|
|
Apr 06
2022
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+3.75%
|
$10,000
$2.9 P/Share
|
|
Mar 29
2022
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.91%
|
$20,000
$2.73 P/Share
|
|
Feb 07
2022
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,334
+6.65%
|
$31,002
$3.58 P/Share
|
|
Feb 04
2022
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+3.9%
|
$15,000
$3.3 P/Share
|
|
Jan 28
2022
|
Markus Sieger Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,075
+5.38%
|
-
|
|
Jan 28
2022
|
Francis Patrick Ostronic Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,065
+4.11%
|
-
|
|
Jan 28
2022
|
Randall M. Toig Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,187
+4.51%
|
-
|
|
Jan 24
2022
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.74%
|
$6,000
$3.75 P/Share
|
|
Jan 19
2022
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
1,132
+1.01%
|
$4,528
$4.0 P/Share
|
|
Jan 19
2022
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+3.58%
|
$15,000
$3.89 P/Share
|
|
Jan 14
2022
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
3,868
+1.74%
|
$15,472
$4.0 P/Share
|
|
Dec 15
2021
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+3.71%
|
$15,000
$3.89 P/Share
|
|
Dec 15
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
3,000
+2.75%
|
$9,000
$3.9 P/Share
|
|
Dec 10
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+4.62%
|
$20,000
$4.4 P/Share
|
|
Dec 03
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
864
+0.87%
|
$3,456
$4.75 P/Share
|
|
Dec 02
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
4,136
+4.08%
|
$16,544
$4.75 P/Share
|
|
Dec 02
2021
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+3.86%
|
$20,000
$4.93 P/Share
|
|
Dec 02
2021
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+4.91%
|
$4,000
$4.98 P/Share
|
|
Dec 01
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.09%
|
$25,000
$5.0 P/Share
|
|
Nov 19
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
10,652
+5.5%
|
$53,260
$5.24 P/Share
|
|
Nov 19
2021
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.01%
|
$25,000
$5.25 P/Share
|
|
Oct 29
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.27%
|
$5,000
$5.9 P/Share
|
|
Sep 27
2021
|
Lise Lund Kjems Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,053
+50.0%
|
-
|
|
Sep 15
2021
|
N Scott Fine Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.18%
|
$30,000
$6.35 P/Share
|
|
Apr 16
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
10,000
+6.33%
|
$60,000
$6.53 P/Share
|
|
Apr 12
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
5,000
+6.99%
|
$35,000
$7.0 P/Share
|
|
Mar 29
2021
|
Jeffrey Tate Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+6.86%
|
$14,000
$7.5 P/Share
|
|
Mar 29
2021
|
Francis Patrick Ostronic Director |
BUY
Open market or private purchase
|
Direct |
3,000
+2.4%
|
$21,000
$7.5 P/Share
|
|
Mar 29
2021
|
Sharon Hemond Hrynkow Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+5.17%
|
$7,000
$7.46 P/Share
|
|
Mar 29
2021
|
Joshua M Fine Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50
+0.3%
|
$350
$7.4 P/Share
|
|
Mar 29
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
10,000
+12.88%
|
$80,000
$8.1 P/Share
|
|
Mar 05
2021
|
Randall M. Toig Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
10,000
+18.49%
|
$50,000
$5.0 P/Share
|
|
Jan 26
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
2,201
+3.68%
|
$13,206
$6.6 P/Share
|
|
Jan 25
2021
|
Markus Sieger Director |
BUY
Open market or private purchase
|
Direct |
7,799
+4.67%
|
$46,794
$6.3 P/Share
|